Metallic Engineered Nanomaterials and Ocular Toxicity: A Current Perspective.

Krista M Cosert, Soohyun Kim, Iman Jalilian, Maggie Chang, Brooke L Gates, Kent E Pinkerton, Laura S Van Winkle, Vijay Krishna Raghunathan, Brian C Leonard, Sara M Thomasy
Author Information
  1. Krista M Cosert: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA.
  2. Soohyun Kim: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA. ORCID
  3. Iman Jalilian: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA.
  4. Maggie Chang: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA.
  5. Brooke L Gates: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA. ORCID
  6. Kent E Pinkerton: Center for Health and the Environment, University of California Davis, Davis, CA 95616, USA.
  7. Laura S Van Winkle: Center for Health and the Environment, University of California Davis, Davis, CA 95616, USA.
  8. Vijay Krishna Raghunathan: Department of Basic Sciences, College of Optometry, University of Houston, Houston, TX 77004, USA. ORCID
  9. Brian C Leonard: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA. ORCID
  10. Sara M Thomasy: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA.

Abstract

The ocular surface, comprised of the transparent cornea, conjunctiva, and protective tear film, forms a protective barrier defending deeper structures of the eye from particulate matter and mechanical trauma. This barrier is routinely exposed to a multitude of naturally occurring and engineered nanomaterials (ENM). Metallic ENMs are particularly ubiquitous in commercial products with a high risk of ocular exposure, such as cosmetics and sunscreens. Additionally, there are several therapeutic uses for metallic ENMs owing to their attractive magnetic, antimicrobial, and functionalization properties. The increasing commercial and therapeutic applications of metallic ENMs come with a high risk of ocular exposure with poorly understood consequences to the health of the eye. While the toxicity of metallic ENMs exposure has been rigorously studied in other tissues and organs, further studies are necessary to understand the potential for adverse effects and inform product usage for individuals whose ocular health may be compromised by injury, disease, or surgical intervention. This review provides an update of current literature on the ocular toxicity of metallic ENMs in vitro and in vivo, as well as the risks and benefits of therapeutic applications of metallic ENMs in ophthalmology.

Keywords

References

  1. Curr Med Chem. 2014;21(33):3837-53 [PMID: 25306903]
  2. Nanomedicine. 2014 Jul;10(5):1109-17 [PMID: 24566275]
  3. Nanomedicine. 2017 Apr;13(3):1147-1155 [PMID: 28065730]
  4. Prog Retin Eye Res. 2013 Jan;32:181-95 [PMID: 23128417]
  5. Nanomaterials (Basel). 2020 Feb 08;10(2): [PMID: 32046269]
  6. Chem Soc Rev. 2011 Mar;40(3):1647-71 [PMID: 21082078]
  7. NanoImpact. 2021 Oct;24:100352 [PMID: 35559825]
  8. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1102-1113 [PMID: 29488395]
  9. Curr Top Med Chem. 2021;21(2):115-125 [PMID: 32962618]
  10. Int J Mol Sci. 2014 Jan 22;15(1):1590-605 [PMID: 24451140]
  11. Cornea. 2017 May;36(5):605-610 [PMID: 28306598]
  12. Adv Drug Deliv Rev. 2006 Nov 15;58(11):1131-5 [PMID: 17097758]
  13. Acta Pharm Sin B. 2017 May;7(3):281-291 [PMID: 28540165]
  14. Trends Cell Biol. 2010 Mar;20(3):142-9 [PMID: 20061152]
  15. Nanomedicine. 2011 Aug;7(4):505-13 [PMID: 21272669]
  16. Part Fibre Toxicol. 2021 Jan 9;18(1):4 [PMID: 33422125]
  17. Curr Top Med Chem. 2015;15(18):1914-29 [PMID: 25961521]
  18. Int J Nanomedicine. 2014 Dec 15;9 Suppl 2:109-26 [PMID: 25565830]
  19. PLoS One. 2014 Aug 21;9(8):e105359 [PMID: 25144684]
  20. Toxicol In Vitro. 2017 Feb;38:179-192 [PMID: 27816503]
  21. Pflugers Arch. 2017 Jan;469(1):135-147 [PMID: 27921210]
  22. Sci Rep. 2018 Jan 25;8(1):1565 [PMID: 29371617]
  23. Mol Pharm. 2016 Sep 6;13(9):2897-905 [PMID: 27482595]
  24. Front Bioeng Biotechnol. 2020 Nov 03;8:549089 [PMID: 33224926]
  25. Materials (Basel). 2018 Jul 06;11(7): [PMID: 29986436]
  26. Adv Drug Deliv Rev. 2009 Jun 21;61(6):457-66 [PMID: 19386275]
  27. Exp Eye Res. 2013 Nov;116:63-74 [PMID: 23978600]
  28. Semin Ophthalmol. 1999 Dec;14(4):223-32 [PMID: 10758223]
  29. Drug Dev Ind Pharm. 2002 May;28(5):473-93 [PMID: 12098838]
  30. Pharmaceutics. 2018 Jan 13;10(1): [PMID: 29342879]
  31. Pharmacol Res. 2020 Nov;161:105115 [PMID: 32750417]
  32. J Appl Biomater Biomech. 2010 Jan-Apr;8(1):1-6 [PMID: 20740415]
  33. Nanotoxicology. 2014 Aug;8 Suppl 1:57-71 [PMID: 24256211]
  34. Mol Pharm. 2021 Feb 1;18(2):506-521 [PMID: 32501716]
  35. Artif Cells Nanomed Biotechnol. 2016 Nov;44(7):1764-73 [PMID: 26523428]
  36. Colloids Surf B Biointerfaces. 2009 Oct 1;73(1):51-7 [PMID: 19481908]
  37. Toxicol Res. 2019 Jul;35(3):287-294 [PMID: 31341558]
  38. Brain Res Bull. 2017 May;131:117-122 [PMID: 28373151]
  39. Nanotoxicology. 2013 Aug;7(5):953-60 [PMID: 22417112]
  40. Mol Vis. 2006 May 26;12:606-15 [PMID: 16760897]
  41. Arch Biochem Biophys. 2019 Jul 15;669:1-10 [PMID: 31112708]
  42. Sci Rep. 2017 Mar 03;7:43092 [PMID: 28256525]
  43. Sci Rep. 2018 Aug 16;8(1):12251 [PMID: 30115953]
  44. Int J Nanomedicine. 2014 Dec 15;9 Suppl 2:93-107 [PMID: 25565829]
  45. Nanoscale. 2016 Mar 28;8(12):6484-9 [PMID: 26949000]
  46. Arch Biochem Biophys. 2020 Apr 15;683:108324 [PMID: 32112740]
  47. Photochem Photobiol. 2014 Nov-Dec;90(6):1324-31 [PMID: 25059545]
  48. J Mater Chem B. 2019 Nov 21;7(43):6759-6769 [PMID: 31593203]
  49. Mater Sci Eng C Mater Biol Appl. 2021 Feb;119:111497 [PMID: 33321598]
  50. Retina. 2008 Jan;28(1):147-9 [PMID: 18185152]
  51. Int J Ophthalmol. 2014 Dec 18;7(6):917-23 [PMID: 25540739]
  52. Curr Eye Res. 2016 Jun;41(6):783-90 [PMID: 26148227]
  53. Front Bioeng Biotechnol. 2020 Feb 25;8:144 [PMID: 32158755]
  54. Biomaterials. 2011 Mar;32(7):1865-71 [PMID: 21145587]
  55. Bioimpacts. 2016;6(1):49-67 [PMID: 27340624]
  56. Environ Pollut. 2018 Dec;243(Pt A):301-307 [PMID: 30189392]
  57. Nanoscale. 2019 Mar 21;11(12):5580-5594 [PMID: 30860532]
  58. Exp Eye Res. 1996 Feb;62(2):155-69 [PMID: 8698076]
  59. Curr Mol Med. 2006 Sep;6(6):651-63 [PMID: 17022735]
  60. Infect Immun. 2006 Dec;74(12):6581-9 [PMID: 17015453]
  61. Regul Toxicol Pharmacol. 2014 Feb;68(1):1-7 [PMID: 24231525]
  62. ACS Nano. 2008 Oct 28;2(10):2121-34 [PMID: 19206459]
  63. Nanotechnology. 2009 Dec 16;20(50):505101 [PMID: 19923650]
  64. Drug Discov Today. 2008 Feb;13(3-4):144-51 [PMID: 18275912]
  65. Arch Ophthalmol. 2007 Apr;125(4):544-50 [PMID: 17420375]
  66. Pharmaceutics. 2012 May 14;4(2):252-75 [PMID: 24300231]
  67. Part Fibre Toxicol. 2014 Oct 08;11:52 [PMID: 25292367]
  68. Reprod Toxicol. 2017 Jan;67:149-164 [PMID: 28088501]
  69. ACS Biomater Sci Eng. 2020 Dec 14;6(12):6587-6597 [PMID: 33320633]
  70. Dermatol Surg. 2000 Apr;26(4):309-14 [PMID: 10759815]
  71. Sci Rep. 2016 Jan 13;6:19395 [PMID: 26759072]
  72. Chem Rev. 2011 Sep 14;111(9):5610-37 [PMID: 21688848]
  73. Nanomedicine. 2017 May;13(4):1459-1472 [PMID: 28232288]
  74. Food Chem Toxicol. 2013 Oct;60:297-301 [PMID: 23933361]
  75. Food Chem Toxicol. 2015 Mar;77:58-63 [PMID: 25556118]
  76. Nanomedicine. 2018 Jan;14(1):63-71 [PMID: 28890107]
  77. Mil Med. 2016 May;181(5 Suppl):232-9 [PMID: 27168578]
  78. Nanotechnology. 2011 Feb 4;22(5):055702 [PMID: 21178234]
  79. Anal Chim Acta. 2015 Jan 1;853:689-695 [PMID: 25467519]
  80. PLoS One. 2013 Jun 14;8(6):e66434 [PMID: 23799103]
  81. Environ Sci Technol. 2008 Jun 15;42(12):4583-8 [PMID: 18605590]
  82. Soft Matter. 2016 Feb 21;12(7):2025-39 [PMID: 26758382]
  83. Nanotechnology. 2010 Jan 22;21(3):035102 [PMID: 19966402]
  84. Cytometry A. 2010 Jul;77(7):677-85 [PMID: 20564539]
  85. Nat Rev Mol Cell Biol. 2016 Sep;17(9):564-80 [PMID: 27353478]
  86. Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6561-6567 [PMID: 27918830]
  87. Chem Soc Rev. 2006 Jul;35(7):583-92 [PMID: 16791330]
  88. Nanomedicine. 2012 Apr;8(3):383-90 [PMID: 21722619]
  89. J Neurosci Methods. 2006 May 15;153(1):154-61 [PMID: 16290199]
  90. Cells. 2020 Mar 10;9(3): [PMID: 32164376]
  91. Water Sci Technol. 2010;61(1):127-33 [PMID: 20057098]
  92. Chem Soc Rev. 2015 Oct 7;44(17):6287-305 [PMID: 26056687]
  93. Toxicol Appl Pharmacol. 2008 Dec 15;233(3):404-10 [PMID: 18930072]
  94. PLoS One. 2019 Apr 9;14(4):e0214876 [PMID: 30964903]
  95. Photodermatol Photoimmunol Photomed. 2011 Apr;27(2):58-67 [PMID: 21392107]
  96. Exp Eye Res. 2018 Jul;172:123-127 [PMID: 29653143]
  97. Nanomedicine. 2017 Aug;13(6):1901-1911 [PMID: 28400160]
  98. Adv Healthc Mater. 2019 Jan;8(1):e1801307 [PMID: 30511808]
  99. Front Pharmacol. 2012 May 09;3:87 [PMID: 22582044]
  100. J Pharm Pharmacol. 2014 Apr;66(4):507-30 [PMID: 24635555]
  101. Int J Nanomedicine. 2020 May 26;15:3695-3716 [PMID: 32547023]
  102. Curr Eye Res. 2020 Aug;45(8):904-913 [PMID: 31852252]
  103. Biomaterials. 2013 May;34(14):3559-70 [PMID: 23433773]
  104. Drug Chem Toxicol. 2019 Jan;42(1):54-59 [PMID: 29871546]
  105. J Photochem Photobiol B. 2018 Jun;183:133-136 [PMID: 29704861]
  106. Toxicol In Vitro. 2016 Dec;37:61-69 [PMID: 27599945]
  107. Toxicol Lett. 2007 Jul 10;171(3):99-110 [PMID: 17566673]
  108. Int J Nanomedicine. 2014 Dec 15;9 Suppl 2:261-9 [PMID: 25565844]
  109. Ocul Surf. 2016 Apr;14(2):224-32 [PMID: 26775550]
  110. Curr Eye Res. 2020 Aug;45(8):931-939 [PMID: 31847595]
  111. Nat Rev Drug Discov. 2003 May;2(5):347-60 [PMID: 12750738]
  112. PLoS One. 2015 Oct 15;10(10):e0140387 [PMID: 26469804]
  113. Environ Toxicol Pharmacol. 2015 Nov;40(3):729-32 [PMID: 26425943]
  114. Macromol Biosci. 2012 May;12(5):608-20 [PMID: 22508445]
  115. Cold Spring Harb Perspect Biol. 2009 Aug;1(2):a002584 [PMID: 20066090]
  116. J Nanobiotechnology. 2016 Oct 24;14(1):73 [PMID: 27776555]
  117. Expert Opin Drug Deliv. 2015;12(11):1767-82 [PMID: 26173446]
  118. Chem Rev. 2014 Aug 13;114(15):7740-81 [PMID: 24927254]
  119. Biochim Biophys Acta. 2011 Mar;1810(3):361-73 [PMID: 20435096]
  120. Nanomedicine (Lond). 2014 Dec;9(18):2803-15 [PMID: 24823434]
  121. Adv Drug Deliv Rev. 2017 Dec 1;122:31-64 [PMID: 28392306]
  122. Cell Signal. 2020 Feb;66:109485 [PMID: 31770579]
  123. Pharmaceutics. 2018 Feb 27;10(1): [PMID: 29495528]
  124. Arch Toxicol. 2013 Jul;87(7):1181-200 [PMID: 23728526]
  125. Nanotoxicology. 2016 Sep;10(7):836-60 [PMID: 27027670]
  126. NanoImpact. 2020 Jan;17: [PMID: 32154443]
  127. Cell Prolif. 2015 Apr;48(2):198-208 [PMID: 25615023]
  128. Pak J Pharm Sci. 2012 Apr;25(2):477-91 [PMID: 22459480]
  129. Front Physiol. 2019 Jan 23;9:1942 [PMID: 30728783]
  130. Arch Pharm Res. 2014 Mar;37(3):404-11 [PMID: 23828754]
  131. Nat Nanotechnol. 2009 Sep;4(9):546-7 [PMID: 19734922]
  132. Mol Med Rep. 2013 Jun;7(6):1767-72 [PMID: 23588968]
  133. BMJ Open. 2013 Nov 07;3(11):e003471 [PMID: 24202057]
  134. Int J Mol Sci. 2011;12(11):8288-301 [PMID: 22174664]
  135. Jpn J Ophthalmol. 2009 May;53(3):249-56 [PMID: 19484444]
  136. J Appl Toxicol. 2019 Jan;39(1):16-26 [PMID: 29943411]
  137. Nanomedicine (Lond). 2018 Jan;13(2):233-249 [PMID: 29199887]
  138. Med Res Rev. 2019 Jan;39(1):302-327 [PMID: 29766541]
  139. Exp Eye Res. 2020 Sep;198:108151 [PMID: 32721426]
  140. Eur J Pharm Sci. 2018 Apr 30;116:26-36 [PMID: 29055734]
  141. Int J Nanomedicine. 2021 Jan 08;16:161-184 [PMID: 33447033]
  142. Invest Ophthalmol Vis Sci. 2013 Jul 24;54(7):4982-90 [PMID: 23766475]
  143. PLoS One. 2011;6(5):e17452 [PMID: 21637340]
  144. Int J Pharm. 2016 Mar 30;501(1-2):96-101 [PMID: 26828672]

Grants

  1. T42 OH008429/NIOSH CDC HHS
  2. U01 ES027288/NIEHS NIH HHS
  3. U01ES027288/NIH HHS
  4. P30EY12576/NIH HHS

Word Cloud

Created with Highcharts 10.0.0metallicocularENMseyeexposuretherapeutictoxicityprotectivebarrierengineerednanomaterialsMetalliccommercialhighriskapplicationshealthsurfacecomprisedtransparentcorneaconjunctivatearfilmformsdefendingdeeperstructuresparticulatemattermechanicaltraumaroutinelyexposedmultitudenaturallyoccurringENMparticularlyubiquitousproductscosmeticssunscreensAdditionallyseveralusesowingattractivemagneticantimicrobialfunctionalizationpropertiesincreasingcomepoorlyunderstoodconsequencesrigorouslystudiedtissuesorgansstudiesnecessaryunderstandpotentialadverseeffectsinformproductusageindividualswhosemaycompromisedinjurydiseasesurgicalinterventionreviewprovidesupdatecurrentliteraturevitrovivowellrisksbenefitsophthalmologyEngineeredNanomaterialsOcularToxicity:CurrentPerspectivecornealwoundhealingnanoparticles

Similar Articles

Cited By